Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Who May Be Eligible (Plain English)

This study is seeking participants who are: - aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. - willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. - do not have worsening or hospitalization for worsening PAH during the qualifying study. - not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. - do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. - not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). - not currently prescribed or taking medicines called as GLP-1 agonist. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * do not have worsening or hospitalization for worsening PAH during the qualifying study. * not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. * do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. * not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). * not currently prescribed or taking medicines called as GLP-1 agonist.

Treatments Being Tested

DRUG

PF-07868489

Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Locations (20)

UCSF Health St. Mary's Hospital
San Francisco, California, United States
Heart and Vascular Center
San Francisco, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Norton Hospital
Louisville, Kentucky, United States
Norton Pulmonary Specialists
Louisville, Kentucky, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Center for Advanced Lung Care
Providence, Rhode Island, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
HUB Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium
London Health Sciences Centre - University Hospital
London, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
CHRU de Brest
Brest, Finistère, France
Centre Hospitalier Universitaire de Saint-Etienne, Hôpital Nord
Saint-Priest-en-Jarez, France
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, Germany